Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Transthyretin Cardiac Amyloidosis: full-pipeline trial registry
3 of 5 indexed Transthyretin Cardiac Amyloidosis trials are currently recruiting.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Transthyretin Cardiac Amyloidosis: 5 US clinical trials tracked, 3 recruiting.
Transthyretin Cardiac Amyloidosis is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Idoven 1903 S.L., running 1 of these trials.
Enrollment posture brief
Registry condition transthyretin-cardiac-amyloidosis
OPEN 3 | RECR 60% | LATE 1 | EARLY 1 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
Transthyretin Cardiac Amyloidosis lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Transthyretin Cardiac Amyloidosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Transthyretin Cardiac Amyloidosis is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Transthyretin Cardiac Amyloidosis research.
Idoven 1903 S.L. accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Transthyretin Cardiac Amyloidosis trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Transthyretin Cardiac Amyloidosis splits between interventional and observational designs.
3 interventional and 2 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
Idoven 1903 S.L.
NCT06978660
Exercise Training in Transthyretin Cardiac Amyloidosis
Brigham and Women's Hospital
NCT05797857
Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation
University of Texas Southwestern Medical Center
NCT05489523
Bronx Transthyretin Amyloid Cardiomyopathy Database
Montefiore Medical Center
NCT06257485
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
Mayo Clinic
NCT04899180
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Transthyretin Cardiac Amyloidosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Transthyretin Cardiac Amyloidosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Transthyretin Cardiac Amyloidosis page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Transthyretin Cardiac Amyloidosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Idoven 1903 S.L. sponsors the most Transthyretin Cardiac Amyloidosis trials on record, review their full trial history before evaluating a specific study. See Idoven 1903 S.L.'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Transthyretin Cardiac Amyloidosis condition card totals 5 registered trials; most-linked intervention 99mTc-PYP; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.